



# New one-pot synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones based on 5-aminopyrazoles and azlactones

Vladislav Yu. Shuvalov<sup>1</sup>, Ekaterina Yu. Vlasova<sup>2</sup>, Tatyana Yu. Zheleznova<sup>1</sup> and Alexander S. Fisyuk<sup>\*1,2</sup>

## Full Research Paper

Open Access

### Address:

<sup>1</sup>Laboratory of New Organic Materials, Omsk State Technical University, 11 Mira Ave., 644050 Omsk, Russian Federation and <sup>2</sup>Department of Organic and Analytical Chemistry, F. M. Dostoevsky Omsk State University, Mira Ave., 55a, 644077 Omsk, Russian Federation

### Email:

Alexander S. Fisyuk\* - fisyuk@chemomsu.ru

\* Corresponding author

### Keywords:

5-aminopyrazole; azlactone; elimination; fluorescence; one-pot synthesis; pyrazolo[3,4-*b*]pyridin-6-one

*Beilstein J. Org. Chem.* **2023**, *19*, 1155–1160.

<https://doi.org/10.3762/bjoc.19.83>

Received: 30 May 2023

Accepted: 14 July 2023

Published: 02 August 2023

This article is part of the thematic issue "Catalytic multi-step domino and one-pot reactions".

Guest Editor: S. Tsogoeva



© 2023 Shuvalov et al.; licensee Beilstein-Institut.  
License and terms: see end of document.

## Abstract

An effective one-pot strategy was developed for the synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones from pyrazolo[3,4-*b*]pyridin-6-ones, obtained by reacting 5-aminopyrazoles with 4-arylidene-2-phenyloxazol-5(4*H*)-ones (azlactones) under solvent-free conditions, through subsequent elimination of a benzamide molecule in a superbasic medium (*t*-BuOK/DMSO). The fluorescent properties of the synthesized compounds were studied. 4-Arylpyrazolo[3,4-*b*]pyridin-6-ones luminesce in the region of 409–440 nm with a quantum yield of 0.09–0.23 when irradiated with UV light.

## Introduction

The pyrazolo[3,4-*b*]pyridine scaffold is present in many biologically active compounds [1-12]. Among them, 4-aryl-substituted derivatives should be distinguished, exhibiting antiviral [13] and anti-inflammatory properties [14], being modulators of estrogen-related receptor alpha [15], JAK1 kinase inhibitor [16], GSK3 [17] and GyrB [8] inhibitors (Figure 1).

Despite the high demand, their synthesis methods are few (Scheme 1). To obtain 4-arylpyrazolo[3,4-*b*]pyridin-6-ones, the only known one-step method is most often used, including the acid-catalyzed condensation of aminopyrazoles with ketoesters [1,16,18] (method A). Its significant disadvantage is the low yields of the target products (11–60%). Yields are also low in

two-stage synthesis methods. The first of them is based on the three-component condensation of aminopyrazoles, Meldrum's acid, and aromatic aldehydes, followed by the oxidation of the intermediate with DDQ [13,16,19] (method B). The second one includes the reaction of an aromatic aldehyde with thioglycolic acid and aminopyrazole, followed by the extrusion of sulfur from the resulting thiazepine [20] (method C). The three-stage synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones, involving the preparation of 3-aryl-*N*-(1*H*-pyrazol-5-yl)propiolamides (method D), also leads to the formation of the target products with low yields [21]. Therefore, the development of a new effective method for the preparation of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones is an urgent task.





Figure 1: Biologically active 4-arylpyrazolo[3,4-*b*]pyridin-6-ones.



Scheme 1: Methods for the synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones.

## Results and Discussion

One of the rational approaches to the synthesis of fused pyridine derivatives is based on the domino reaction of enamines with azlactones [22–30]. We have previously reported a plausible mechanism of such reactions [22,25]. 1*H*-Pyrazol-5-amines also enter into similar transformations with azlactones in various solvents. The yields of tetrahydro-1*H*-pyrazolo[3,4-*b*]pyridones **3** obtained by this method vary widely [31–33]. Solvent-free reactions are convenient from both economic and environmental points of view. We obtained tetrahydro-1*H*-pyrazolo[3,4-*b*]pyridinone **3a** by heating 5-aminopyrazole **1** with azlactone **2a** in the absence of solvent at 150 °C in 62% yield (Table 1). For compound **3a**, the possibility of benzamide elimination was studied. The benzamide fragment is a poor leaving group; however, in a superbasic medium, we were able to eliminate this group in compound **3a**. In order to select optimal synthesis conditions, we heated compound **3a** in DMSO at temperatures from 90 to 150 °C for 1.5, 3.5 and 6 h in the presence of KOH or *t*-BuOK (Table 1).

The best yield of 4-phenylpyrazolo[3,4-*b*]pyridin-6-one **4a** (81%) was achieved at 150 °C in DMSO containing 1.5 equiv of *t*-BuOK for 1.5 h. Obviously, the preparation of

4-phenylpyrazolo[3,4-*b*]pyridin-6-one **4a** could be carried out as one-pot synthesis, without isolation of the intermediate dihydro derivative **3a**. In this case, the solvent (DMSO) could be added at the stage of obtaining dihydro derivative **3a** or introduced into the reaction together with *t*-BuOK. We have explored both variants. When intermediate **3a** was obtained under solvent-free conditions followed by the addition of *t*-BuOK in DMSO, the yield of pyrazolo[3,4-*b*]pyridin-6-one **4a** was higher (73%, Table 1, entry 5) than when performing the reaction in a solvent (60%, Table 1, entry 6). Therefore, this procedure was used for the synthesis of compounds **4b–i**, **9a**, **10a**. The yields of pyrazolo[3,4-*b*]pyridin-6-ones **4a–i**, **9a**, **10a** obtained by this method are in the range of 55–75% (Scheme 2).

It should be noted that for compounds containing an electron-donating substituent in the C-4 position, such as 4-methoxyphenyl- (**4c**), 3,4-dimethoxyphenyl- (**4d**), 3,4,5-trimethoxyphenyl- (**4e**), 2-furyl- (**4h**) and 2-thienyl- (**4i**), the product yields are reduced to 55–60% (Scheme 2).

All the compounds obtained are colorless crystalline substances. When dissolved, they produce colorless solutions exhibiting




distinct fluorescent properties with blue emission when exposed to UV light. We recorded absorption and fluorescence spectra of ethanolic solutions of compounds **4a–i**, **9a**, and **10a**. The emission and absorption spectra of all the compounds differ slightly from each other. Their spectral parameters are presented in Table 2.

In the UV spectra of ethanolic solutions of compounds **4a–i**, **9a**, and **10a**, a band with a maximum at 260–265 nm is observed, which has a shoulder at 300–305 nm. These signals seem to correspond to  $\pi$ - $\pi^*$  and  $n$ - $\pi^*$  transitions. In the luminescence spectra of compounds **4a–i**, **9a**, and **10a**, there is one broadened band with an emission maximum at 409–440 nm (Figure 2).

**Table 2:** Data of absorption and fluorescence spectra of compounds **4a–i**, **9a**, and **10a**.<sup>a</sup>

Compound	$\max \lambda_{\text{abs}}$ , nm	UV-vis		$\lambda_{\text{ex}}$ , nm	$\max \lambda_{\text{em}}$ , nm	Photoluminescence	
		$\epsilon$ , $10^3$ , $\text{M}^{-1}\cdot\text{cm}^{-1}$ ( $\lambda$ , nm)				Stokes shift, nm; eV	Quantum yield $\Phi_{\text{fl}}^{\text{b}}$
<b>4a</b>	260; 302	$30.3 \pm 0.7$ (260)		300; 320	419	117; 1.15	$0.22 \pm 0.01$
<b>4b</b>	260; 302	$38.3 \pm 0.7$ (260)		300; 320	428	126; 1.21	$0.23 \pm 0.01$
<b>4c</b>	262; 302	$22.2 \pm 0.8$ (262)		300; 320	409	107; 1.07	$0.16 \pm 0.01$
<b>4d</b>	260; 301	$35.1 \pm 0.9$ (260)		300; 320	414	113; 1.12	$0.15 \pm 0.01$
<b>4e</b>	262; 301	$22.7 \pm 0.9$ (262)		300; 320	416	115; 1.14	$0.18 \pm 0.01$
<b>4f</b>	260; 302	$27.6 \pm 0.8$ (260)		300; 320	415	113; 1.12	$0.20 \pm 0.01$
<b>4g</b>	261; 300	$41.5 \pm 0.9$ (261)		300; 320	411	111; 1.12	$0.20 \pm 0.01$
<b>4h</b>	265; 305	$32.4 \pm 1.0$ (265)		300; 310	421	116; 1.12	$0.23 \pm 0.01$
<b>4i</b>	263; 301	$26.2 \pm 0.8$ (263)		300; 310	431	130; 1.24	$0.09 \pm 0.00$
<b>9a</b>	259; 303	$40.0 \pm 0.9$ (261)		305	433	130; 1.23	$0.19 \pm 0.01$
<b>10a</b>	261; 288	$34.9 \pm 0.5$ (259)		290	440	152; 1.49	$0.11 \pm 0.01$

<sup>a</sup>In EtOH solution,  $c = 1.0 \cdot 10^{-5} \text{ mol}\cdot\text{L}^{-1}$ . <sup>b</sup>Quantum yield determined relative to quinine sulfate standard in 0.5 M  $\text{H}_2\text{SO}_4$  ( $\Phi_{\text{r}} = 0.546$ ).



**Figure 2:** Normalized absorption and fluorescence spectra of solutions of compounds **4a–i**, **9a**, and **10a** in EtOH.

Their diluted alcohol solutions luminesce with a quantum yield of 0.09–0.23. Pyrazolo[3,4-*b*]pyridinones **4a–i**, **9a**, and **10a** are characterized by an abnormally high Stokes shift (107–152 nm, 1.07–1.49 eV, Table 2). Such luminophores, which are colorless in daylight but become colored when irradiated with UV light, are used in forensics, in protection against forgery of banknotes, securities, and other important documents [34].

## Conclusion

In summary, we developed a simple one-pot synthesis of 4-arylpyrazolo[3,4-*b*]pyridin-6-ones, based on the solvent-free reaction of the available starting compounds 5-aminopyrazoles **1**, **5**, **6** and azlactones **2a–i**, followed by heating the resulting intermediate in DMSO in the presence of *t*-BuOK. Photophysical properties of the obtained compounds were studied.

## Supporting Information

### Supporting Information File 1

Experimental procedures, characterization data, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for all new compounds.

[<https://www.beilstein-journals.org/bjoc/content/supplementary/1860-5397-19-83-S1.pdf>]

## Funding

This work was supported by the Russian Science Foundation (grant No. 22-13-00356).

## ORCID® iDs

Vladislav Yu. Shuvalov - <https://orcid.org/0000-0003-2890-1671>

Ekaterina Yu. Vlasova - <https://orcid.org/0009-0008-0177-8232>

Tatyana Yu. Zheleznova - <https://orcid.org/0000-0002-0915-1724>

Alexander S. Fisuyuk - <https://orcid.org/0000-0001-6191-9297>

## Preprint

A non-peer-reviewed version of this article has been previously published as a preprint: <https://doi.org/10.3762/bxiv.2023.23.v1>

## References

- Cross, J. B.; Zhang, J.; Yang, Q.; Mesleh, M. F.; Romero, J. A. C.; Wang, B.; Bevan, D.; Poutsiaika, K. M.; Epie, F.; Moy, T.; Daniel, A.; Shotwell, J.; Chamberlain, B.; Carter, N.; Andersen, O.; Barker, J.; Ryan, M. D.; Metcalf, C. A., III; Silverman, J.; Nguyen, K.; Lippa, B.; Dolle, R. E. *ACS Med. Chem. Lett.* **2016**, *7*, 374–378. doi:10.1021/acsmedchemlett.5b00368
- Luo, D.; Guo, Z.; Zhao, X.; Wu, L.; Liu, X.; Zhang, Y.; Zhang, Y.; Deng, Z.; Qu, X.; Cui, S.; Wan, S. *Eur. J. Med. Chem.* **2022**, *227*, 113923. doi:10.1016/j.ejmech.2021.113923
- Tucker, T. J.; Sisko, J. T.; Tynebor, R. M.; Williams, T. M.; Felock, P. J.; Flynn, J. A.; Lai, M.-T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnell, R.; Prasad, S.; Reid, J. C.; Sanchez, R.; Torrent, M.; Vacca, J. P.; Wan, B.-L.; Yan, Y. *J. Med. Chem.* **2008**, *51*, 6503–6511. doi:10.1021/jm800856c
- Hamblin, J. N.; Angell, T. D. R.; Ballantine, S. P.; Cook, C. M.; Cooper, A. W. J.; Dawson, J.; Delves, C. J.; Jones, P. S.; Lindvall, M.; Lucas, F. S.; Mitchell, C. J.; Neu, M. Y.; Ranshaw, L. E.; Solanke, Y. E.; Somers, D. O.; Wiseman, J. O. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4237–4241. doi:10.1016/j.bmcl.2008.05.052
- Barghash, R. F.; Eldehna, W. M.; Kovalová, M.; Vojáčková, V.; Kryštof, V.; Abdel-Aziz, H. A. *Eur. J. Med. Chem.* **2022**, *227*, 113952. doi:10.1016/j.ejmech.2021.113952
- Ribeiro, J. L. S.; Soares, J. C. A. V.; Portapilla, G. B.; Providello, M. V.; Lima, C. H. S.; Muri, E. M. F.; de Albuquerque, S.; Dias, L. R. S. *Bioorg. Med. Chem.* **2021**, *29*, 115855. doi:10.1016/j.bmc.2020.115855
- Sharma, P. K.; Singh, K.; Kumar, S.; Kumar, P.; Dhawan, S. N.; Lal, S.; Ulbrich, H.; Dannhardt, G. *Med. Chem. Res.* **2011**, *20*, 239–244. doi:10.1007/s00044-010-9312-7
- Mesleh, M. F.; Cross, J. B.; Zhang, J.; Kahmann, J.; Andersen, O. A.; Barker, J.; Cheng, R. K.; Felicetti, B.; Wood, M.; Hadfield, A. T.; Scheich, C.; Moy, T. I.; Yang, Q.; Shotwell, J.; Nguyen, K.; Lippa, B.; Dolle, R.; Ryan, M. D. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1314–1318. doi:10.1016/j.bmcl.2016.01.009
- Lu, Y.; Mao, F.; Li, X.; Zheng, X.; Wang, M.; Xu, Q.; Zhu, J.; Li, J. *J. Med. Chem.* **2017**, *60*, 5099–5119. doi:10.1021/acs.jmedchem.7b00468
- Wager, T. T. Pyrazolo[3,4-*c*]pyridines as gsk-3 inhibitors. PCT Pat. Appl. WO2005000303A1, Jan 6, 2005.
- Behnke, D.; Cotesta, S.; Hintermann, S.; Fendt, M.; Gee, C. E.; Jacobson, L. H.; Laue, G.; Meyer, A.; Wagner, T.; Badiger, S.; Chaudhari, V.; Chebrolu, M.; Pandit, C.; Hoyer, D.; Betschart, C. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 5555–5560. doi:10.1016/j.bmcl.2015.10.055
- Choi, P. J.; Lu, G.-L.; Sutherland, H. S.; Giddens, A. C.; Franzblau, S. G.; Cooper, C. B.; Denny, W. A.; Palmer, B. D. *Tetrahedron Lett.* **2022**, *90*, 153611. doi:10.1016/j.tetlet.2021.153611
- Plempner, R. K.; Lee, E.; Vernachio, J.; Bourque, E. Bicyclic fused pyrazole derivatives for the treatment of rsv. PCT Pat. Appl. WO2017196982A1, Nov 16, 2017.
- Uchikawa, O.; Mitsui, K.; Asakawa, A.; Morimoto, S.; Yamamoto, M.; Kimura, H.; Moriya, T.; Mizuno, M. Condensed pyrazole derivatives, process for producing the same and use thereof. U.S. Patent US2003187014A1, Oct 2, 2003.
- Lemmers, J. G. H.; Deretey, E.; Klomp, J. P. G.; Cals, J. M. G. B.; Oubrie, A. Estrogen-related receptor alpha (ERRα) modulators. PCT Pat. Appl. WO2021001453A1, Jan 7, 2021.
- Hansen, B. B.; Jepsen, T. H.; Larsen, M.; Sindet, R.; Vifian, T.; Burhardt, M. N.; Larsen, J.; Seitzberg, J. G.; Carnerup, M. A.; Jerre, A.; Mølck, C.; Lovato, P.; Rai, S.; Nasipreddy, V. R.; Ritzén, A. *J. Med. Chem.* **2020**, *63*, 7008–7032. doi:10.1021/acs.jmedchem.0c00359
- Wager, T. GSK-3 inhibitors. U.S. Patent US2005026946A1, Feb 3, 2005.
- Ratajczyk, J. D.; Swett, L. R. *J. Heterocycl. Chem.* **1975**, *12*, 517–522. doi:10.1002/jhet.5570120315
- Quiroga, J.; Hormaza, A.; Insuasty, B.; Márquez, M. *J. Heterocycl. Chem.* **1998**, *35*, 409–412. doi:10.1002/jhet.5570350225

20. Swett, L. R.; Ratajczyk, J. D.; Nordeen, C. W.; Aynilian, G. H. *J. Heterocycl. Chem.* **1975**, *12*, 1137–1142. doi:10.1002/jhet.5570120611
21. Minami, S.; Tomita, M.; Kawaguchi, K. *Chem. Pharm. Bull.* **1972**, *20*, 1716–1728. doi:10.1248/cpb.20.1716
22. Shuvalov, V. Y.; Samsonenko, A. L.; Rozhkova, Y. S.; Morozov, V. V.; Shklyayev, Y. V.; Fisyuk, A. S. *ChemistrySelect* **2021**, *6*, 11265–11269. doi:10.1002/slct.202103028
23. Shuvalov, V. Yu.; Chernenko, S. A.; Shatsauskas, A. L.; Samsonenko, A. L.; Dmitriev, M. V.; Fisyuk, A. S. *Chem. Heterocycl. Compd.* **2021**, *57*, 764–771. doi:10.1007/s10593-021-02980-w
24. Shuvalov, V. Y.; Rozhkova, Y. S.; Plekhanova, I. V.; Kostyuchenko, A. S.; Shklyayev, Y. V.; Fisyuk, A. S. *Chem. Heterocycl. Compd.* **2022**, *58*, 7–14. doi:10.1007/s10593-022-03050-5
25. Shuvalov, V. Yu.; Fisyuk, A. S. *Synthesis* **2023**, *55*, 1267–1273. doi:10.1055/a-1993-3714
26. Cunha, S.; dos Santos Filho, R. F.; Saraiva, K. H.; Azevedo-Santos, A. V.; Menezes, D. *Tetrahedron Lett.* **2013**, *54*, 3366–3370. doi:10.1016/j.tetlet.2013.04.055
27. Chen, X.; Zhu, D.; Wang, X.; Yan, S.; Lin, J. *Tetrahedron* **2013**, *69*, 9224–9236. doi:10.1016/j.tet.2013.08.052
28. Vanden Eynde, J. J.; Labuche, N.; Van Haverbeke, Y. *Synth. Commun.* **1997**, *27*, 3683–3690. doi:10.1080/00397919708007288
29. Worayuthakarn, R.; Nealmongkol, P.; Ruchirawat, S.; Thasana, N. *Tetrahedron* **2012**, *68*, 2864–2875. doi:10.1016/j.tet.2012.01.094
30. Liu, X.-Q.; Liu, Y.-Q.; Shao, X.-S.; Xu, Z.-P.; Xu, X.-Y.; Li, Z. *Chin. Chem. Lett.* **2016**, *27*, 7–10. doi:10.1016/j.ccllet.2015.10.002
31. Shi, F.; Zhang, J.; Tu, S.; Jia, R.; Zhang, Y.; Jiang, B.; Jiang, H. *J. Heterocycl. Chem.* **2007**, *44*, 1013–1017. doi:10.1002/jhet.5570440506
32. Kim, H. S.; Hammill, J. T.; Scott, D. C.; Chen, Y.; Min, J.; Rector, J.; Singh, B.; Schulman, B. A.; Guy, R. K. *J. Med. Chem.* **2019**, *62*, 8429–8442. doi:10.1021/acs.jmedchem.9b00410
33. Kim, H. S.; Hammill, J. T.; Scott, D. C.; Chen, Y.; Rice, A. L.; Pistel, W.; Singh, B.; Schulman, B. A.; Guy, R. K. *J. Med. Chem.* **2021**, *64*, 5850–5862. doi:10.1021/acs.jmedchem.1c00035
34. Ulyankin, E. B.; Bogza, Y. P.; Kostyuchenko, A. S.; Chernenko, S. A.; Samsonenko, A. L.; Shatsauskas, A. L.; Yurpalov, V. L.; Fisyuk, A. S. *Synlett* **2021**, *32*, 790–794. doi:10.1055/a-1392-2209

## License and Terms

This is an open access article licensed under the terms of the Beilstein-Institut Open Access License Agreement (<https://www.beilstein-journals.org/bjoc/terms>), which is identical to the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0>). The reuse of material under this license requires that the author(s), source and license are credited. Third-party material in this article could be subject to other licenses (typically indicated in the credit line), and in this case, users are required to obtain permission from the license holder to reuse the material.

The definitive version of this article is the electronic one which can be found at: <https://doi.org/10.3762/bjoc.19.83>